CVS Health Corporation
CVS Health Corporation (CVS) Stock Competitors & Peer Comparison
See (CVS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CVS | $96.03 | +0.15% | 122.5B | 42.11 | $2.28 | +2.76% |
| UNH | $391.08 | -0.70% | 355.2B | 29.47 | $13.27 | +2.26% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $394.05 | +0.35% | 85.6B | 16.70 | $23.60 | +1.73% |
| CI | $286.67 | +0.49% | 75.8B | 11.91 | $24.08 | +2.12% |
| HUM | $306.01 | +0.29% | 36.7B | 32.66 | $9.37 | +1.16% |
| CNC | $58.22 | -0.09% | 28.7B | -4.46 | -$13.05 | N/A |
| MOH | $184.87 | -0.06% | 9.6B | 49.39 | $3.74 | N/A |
| OSCR | $25.30 | +8.49% | 6.6B | -46.85 | -$0.54 | N/A |
| ALHC | $16.29 | +3.53% | 3.4B | 162.80 | $0.10 | N/A |
Stock Comparison
CVS vs UNH Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, UNH has a market cap of 355.2B. Regarding current trading prices, CVS is priced at $96.03, while UNH trades at $391.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas UNH's P/E ratio is 29.47. In terms of profitability, CVS's ROE is +0.04%, compared to UNH's ROE of +0.12%. Regarding short-term risk, CVS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check UNH's competition here
CVS vs ANTM Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CVS is priced at $96.03, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CVS's ROE is +0.04%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, CVS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ANTM's competition here
CVS vs ELV Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, ELV has a market cap of 85.6B. Regarding current trading prices, CVS is priced at $96.03, while ELV trades at $394.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas ELV's P/E ratio is 16.70. In terms of profitability, CVS's ROE is +0.04%, compared to ELV's ROE of +0.12%. Regarding short-term risk, CVS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ELV's competition here
CVS vs CI Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, CI has a market cap of 75.8B. Regarding current trading prices, CVS is priced at $96.03, while CI trades at $286.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas CI's P/E ratio is 11.91. In terms of profitability, CVS's ROE is +0.04%, compared to CI's ROE of +0.15%. Regarding short-term risk, CVS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CI's competition here
CVS vs HUM Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, HUM has a market cap of 36.7B. Regarding current trading prices, CVS is priced at $96.03, while HUM trades at $306.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas HUM's P/E ratio is 32.66. In terms of profitability, CVS's ROE is +0.04%, compared to HUM's ROE of +0.06%. Regarding short-term risk, CVS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check HUM's competition here
CVS vs CNC Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, CNC has a market cap of 28.7B. Regarding current trading prices, CVS is priced at $96.03, while CNC trades at $58.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas CNC's P/E ratio is -4.46. In terms of profitability, CVS's ROE is +0.04%, compared to CNC's ROE of -0.29%. Regarding short-term risk, CVS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CNC's competition here
CVS vs MOH Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, MOH has a market cap of 9.6B. Regarding current trading prices, CVS is priced at $96.03, while MOH trades at $184.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas MOH's P/E ratio is 49.39. In terms of profitability, CVS's ROE is +0.04%, compared to MOH's ROE of +0.04%. Regarding short-term risk, CVS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check MOH's competition here
CVS vs OSCR Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, OSCR has a market cap of 6.6B. Regarding current trading prices, CVS is priced at $96.03, while OSCR trades at $25.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas OSCR's P/E ratio is -46.85. In terms of profitability, CVS's ROE is +0.04%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, CVS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check OSCR's competition here
CVS vs ALHC Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, ALHC has a market cap of 3.4B. Regarding current trading prices, CVS is priced at $96.03, while ALHC trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas ALHC's P/E ratio is 162.80. In terms of profitability, CVS's ROE is +0.04%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, CVS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check ALHC's competition here
CVS vs CLOV Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, CLOV has a market cap of 1.8B. Regarding current trading prices, CVS is priced at $96.03, while CLOV trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas CLOV's P/E ratio is -28.25. In terms of profitability, CVS's ROE is +0.04%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, CVS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CLOV's competition here
CVS vs BHG Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CVS is priced at $96.03, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas BHG's P/E ratio is -0.12. In terms of profitability, CVS's ROE is +0.04%, compared to BHG's ROE of -0.70%. Regarding short-term risk, CVS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BHG's competition here
CVS vs CABR Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, CABR has a market cap of 13M. Regarding current trading prices, CVS is priced at $96.03, while CABR trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas CABR's P/E ratio is -1.91. In terms of profitability, CVS's ROE is +0.04%, compared to CABR's ROE of -3.00%. Regarding short-term risk, CVS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check CABR's competition here
CVS vs BMGL Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, BMGL has a market cap of 12.4M. Regarding current trading prices, CVS is priced at $96.03, while BMGL trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas BMGL's P/E ratio is -1.47. In terms of profitability, CVS's ROE is +0.04%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CVS is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check BMGL's competition here
CVS vs MRAI Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, MRAI has a market cap of 4.7M. Regarding current trading prices, CVS is priced at $96.03, while MRAI trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas MRAI's P/E ratio is -0.09. In terms of profitability, CVS's ROE is +0.04%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, CVS is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CVS.Check MRAI's competition here
CVS vs AET Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, AET has a market cap of 0. Regarding current trading prices, CVS is priced at $96.03, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas AET's P/E ratio is N/A. In terms of profitability, CVS's ROE is +0.04%, compared to AET's ROE of +0.11%. Regarding short-term risk, CVS is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check AET's competition here
CVS vs UAM Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CVS is priced at $96.03, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas UAM's P/E ratio is N/A. In terms of profitability, CVS's ROE is +0.04%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CVS is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check UAM's competition here
CVS vs MGLN Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CVS is priced at $96.03, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CVS's ROE is +0.04%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CVS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check MGLN's competition here
CVS vs GTS Comparison May 2026
CVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVS stands at 122.5B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CVS is priced at $96.03, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVS currently has a P/E ratio of 42.11, whereas GTS's P/E ratio is 10.41. In terms of profitability, CVS's ROE is +0.04%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CVS is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CVS.Check GTS's competition here